Business Standard

Dr Reddy's Labs Q4 PAT falls 76% on pricing pressure, low export benefit

Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review

reddy, dr reddy's
Premium

Dr Reddy's laboratory

Sohini Das Mumbai
Hyderabad-based Dr Reddy’s Laboratories (DRL) has posted a 76 per cent year-on-year (YoY) dip in profit after tax (PAT) to Rs 88 crore in Q4FY22 driven by pricing pressure in North America and Europe, lower export benefits, and an increase in the inventory provisions.

The revenue was up 15 per cent to Rs 5,437 crore for the quarter under review. For the full year, Dr Reddy’s posted a 13 per cent growth in revenues to Rs 21,439 crore, while its net profit was up 37 per cent to Rs 2,357 crore.

Dr Reddy’s stock was trading up 0.74 per cent

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 19 2022 | 2:50 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com